期刊
GUT
卷 65, 期 9, 页码 1494-1504出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2014-308392
关键词
-
资金
- National Natural Science Foundation of China [81372615, 81200264, 81472262, 81230057]
- National High Technology Research and Development Program (863 Program) [2014AA020803]
- Shanghai Science and Technology Development Fund [12140902300, 12410707400]
- Shanghai Health System Outstanding Young Talent Training Plan [XYQ2013118]
Objective Long non-coding RNAs (lncRNAs) are emerging as key molecules in cancers, yet their potential molecular mechanisms are not well understood. The objective of this study is to examine the expression and functions of lncRNAs in the development of colorectal cancer (CRC). Methods LncRNA expression profiling of CRC, adenoma and normal colorectal tissues was performed to identify tumour-related lncRNAs involved in colorectal malignant transformation. Then, we used quantitative reverse transcription PCR assays to measure the tumour-related lncRNA and to assess its association with survival and response to adjuvant chemotherapy in 252 patients with CRC. The mechanisms of CCAL function and regulation in CRC were examined using molecular biological methods. Results We identified colorectal cancer-associated lncRNA (CCAL) as a key regulator of CRC progression. Patients whose tumours had high CCAL expression had a shorter overall survival and a worse response to adjuvant chemotherapy than patients whose tumours had low CCAL expression. CCAL promoted CRC progression by targeting activator protein 2 alpha (AP-2 alpha), which in turn activated Wnt/beta-catenin pathway. CCAL induced multidrug resistance (MDR) through activating Wnt/beta-catenin signalling by suppressing AP-2 alpha and further upregulating MDR1/P-gp expression. In addition, we found that histone H3 methylation and deacetylases contributed to the upregulation of CCAL in CRC. Conclusions Our results suggest that CCAL is a crucial oncogenic regulator involved in CRC tumorigenesis and progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据